These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25356785)

  • 1. Emerging drugs for hyperlipidaemia: an update.
    Florentin M; Kostapanos MS; Kei A; Elisaf MS
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):471-88. PubMed ID: 25356785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for hyperlipidemia.
    Paras C; Hussain MM; Rosenson RS
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):433-51. PubMed ID: 20423271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel pharmacotherapies of familial hyperlipidemia.
    Drakopoulou M; Toutouzas K; Stefanadis C
    Pharmacol Ther; 2013 Sep; 139(3):301-12. PubMed ID: 23639874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data.
    Strilchuk L; Fogacci F; Cicero AF
    Expert Opin Drug Saf; 2019 Jul; 18(7):611-621. PubMed ID: 31100030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging options in the treatment of dyslipidemias: a bright future?
    Florentin M; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Emerg Drugs; 2011 Jun; 16(2):247-70. PubMed ID: 21323473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
    Gaudet D; Drouin-Chartier JP; Couture P
    Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?
    Santos RD
    Atheroscler Suppl; 2014 Sep; 15(2):19-25. PubMed ID: 25257073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational therapies for the treatment of atherosclerosis.
    Tomkin GH; Owens D
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1411-21. PubMed ID: 24857672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Looking into the crystal ball-upcoming drugs for dyslipidemia.
    George M; Selvarajan S; Muthukumar R; Elangovan S
    J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):11-20. PubMed ID: 25079474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.
    Wierzbicki AS; Hardman TC; Viljoen A
    Expert Opin Investig Drugs; 2012 May; 21(5):667-76. PubMed ID: 22493980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond statins: lipid management to reduce cardiovascular risk.
    Schuck RN; Mendys PM; Simpson RJ
    Pharmacotherapy; 2013 Jul; 33(7):754-64. PubMed ID: 23606278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New approaches for the treatment of dyslipidemia].
    Mostaza JM; Lahoz C
    Med Clin (Barc); 2014 Apr; 142(7):306-9. PubMed ID: 23768860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating bempedoic acid for the treatment of hyperlipidaemia.
    Penson P; McGowan M; Banach M
    Expert Opin Investig Drugs; 2017 Feb; 26(2):251-259. PubMed ID: 28064554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of the new frontiers in the treatment of atherogenic dyslipidemias.
    Rached FH; Chapman MJ; Kontush A
    Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.